• A budget 2026-27 scheme focusing on transforming India into a biomanufacturing hub.
  • The initiative, with a ₹10,000 crore, five-year outlay, focuses on making India a global innovator.
  • Biopharma involves the production, manufacturing, or extraction of therapies through biological organisms, such as human cells, fungi, or microbes.

What needs to be known?

  • Will help in capturing 5% of the global biopharmaceutical market share.
  • Examples of biopharmaceuticals include vaccines, antibody treatments, gene therapies, cell implants, modern insulin, and recombinant protein drugs.
  • Establishment of National Institutes of Pharmaceutical Education and Research (NIPERs) and the upgradation of seven existing NIPERs to strengthen the scheme.
  • Creation of a large-scale clinical research ecosystem.
  • Enhancing the capacity of the Central Drugs Standard Control Organisation (CDSCO)

 

Central Drugs Standard Control Organisation (CDSCO) 

  • CDSCO is the National Regulatory Authority responsible for ensuring the quality, safety, and efficacy of drugs, cosmetics, and medical devices. Headed by the Drugs Controller General of India  in  Delhi, it regulates imports, approves new drugs, and sets standards.

 

Source: The Hindu

📄 Download PDF